middle.news
Noxopharm Advances Sofra Platform with Cancer Data and FDA Trial Prep
8:26am on Wednesday 22nd of July, 2026 AEST
•
Biotechnology
Read Story
Noxopharm Advances Sofra Platform with Cancer Data and FDA Trial Prep
8:26am on Wednesday 22nd of July, 2026 AEST
Key Points
Sofra platform boosts TLR8 activity for cancer therapy
Collaboration with CSL and InhaTarget expands applications
SOF-SKN manufacturing commenced ahead of clinical trial
Pre-IND FDA meeting preparation underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE